Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Sep;42(6):685-95.
doi: 10.1111/apt.13331. Epub 2015 Jul 22.

Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

K Ashida  1 , Y Sakurai  2 , A Nishimura  2 , K Kudou  2 , N Hiramatsu  3 , E Umegaki  4 , K Iwakiri  5 , T Chiba  6
Affiliations
Randomized Controlled Trial

Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

K Ashida et al. Aliment Pharmacol Ther. 2015 Sep.

Abstract

Background: The potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer clinical advantages over conventional therapy for acid-related disorders.

Aim: To investigate the efficacy and safety of VPZ in patients with erosive oesophagitis (EO).

Methods: In this multicentre, randomised, double-blind, parallel-group, dose-ranging study, patients ≥20 years with endoscopically confirmed EO [Los Angeles (LA) grades A-D] received VPZ 5, 10, 20 or 40 mg, or lansoprazole (LPZ) 30 mg once daily for 8 weeks. The primary endpoint was the proportion of healed EO subjects as shown by endoscopy at week 4.

Results: A total of 732 subjects received VPZ or LPZ. The proportion of healed EO subjects at week 4 was 92.3%, 92.5%, 94.4%, 97.0% and 93.2%, respectively, with VPZ 5, 10, 20 and 40 mg and LPZ 30 mg. All VPZ doses were non-inferior to LPZ when adjusted for baseline LA grades A/B and C/D. Among those with LA grades C/D, the proportions of healed EO subjects were 87.3%, 86.4%, 100%, 96.0% and 87.0%, respectively, with VPZ 5, 10, 20 and 40 mg and LPZ 30 mg. The incidence of adverse events was similar across the groups.

Conclusions: Vonoprazan was effective and non-inferior to LPZ in healing EO. VPZ 20 mg or higher was highly efficacious for severe EO (LA grades C/D). VPZ was associated with no safety concern during this 8-week study, while there was a dose-dependent increase in serum gastrin. Once-daily VPZ 20 mg is the recommended clinical dose for treating EO.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time course of arithmetic mean serum gastrin concentration (a), and pepsinogen I and II concentrations (b, c) (SAS). LPZ, lansoprazole; VPZ, vonoprazan. *P < 0.0001 for VPZ 10, 20 and 40 mg vs. LPZ 30 mg. Each bar shows the standard deviation.
See this image and copyright information in PMC

References

    1. Chiba N, De Gara CJ, Wilkinson JM, et al Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta‐analysis. Gastroenterology 1997; 112: 1798–810. - PubMed
    1. van Pinxteren B, Numans ME, Lau J, et al Short‐term treatment of gastroesophageal reflux disease. J Gen Intern Med 2003; 18: 755–63. - PMC - PubMed
    1. Edwards SJ, Lind T, Lundell L, et al Systematic review: standard‐ and double‐dose proton pump inhibitors for the healing of severe erosive oesophagitis – a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol Ther 2009; 30: 547–56. - PubMed
    1. Fennerty MB, Johanson JF, Hwang C, et al Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005; 21: 455–63. - PubMed
    1. Vakil NB, Shaker R, Johnson DA, et al The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6‐month, randomized, double‐blind, placebo‐controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927–35. - PubMed

Publication types

LinkOut - more resources